ImClone and Bristol-Myers Squibb claim positive results for Erbitux in lung cancer

NEW YORK (AP) - ImClone Systems Inc. and Bristol-Myers Squibb Co. claimed Tuesday that the drug Erbitux improved the survival rate of patients with the most common type of lung cancer in a late-stage study. ImClone shares jumped 18 per cent....More